Back to results
US 2012/0252828 A1Published application
Pyridoquinazolinone m1 receptor positive allosteric modulators
AssigneeMerck Sharp & Dohme Corp.
InventorsScott D. Kuduk, Ronald K. Chang, Thomas J. Greshock
Life of this patent
Estimating the term…
Abstract
The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Claims21
A compound of formula (I):
- wherein R1 is selected from the group consisting of
- (1) —C6-10 aryl, or
- (2) heteroaryl, wherein the heteroaryl is an aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
- wherein each aryl or heteroaryl is optionally substituted with one or more R2 group;
- R2 is selected from the group consisting of
- (1) halogen,
- (2) —C1-6 alkyl,
- (3) —C2-8 alkenyl,
- (4) —O—C1-6 alkyl,
- (5) —S—C1-6 alkyl,
- (6) —C(═O)—(O)n—R4,
- (7) —C6-10 aryl,
- (8) heteroaryl, which is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
- (9) —NR5R6,
- wherein said alkyl, alkenyl, aryl or heteroaryl R2 group is optionally substituted with one or more
- (a) halogen,
- (b) —C1-6 alkyl,
- (c) —C3-8 cycloalkyl,
- (d) —NR7R8,
- (e) —O—C1-6 alkyl,
- (f) C6-10 aryl,
- (g) CN, or
- (h) hydroxyl
- wherein said alkyl, cycloalkyl or aryl is optionally substituted with one or more
- (i) halogen,
- (ii) hydroxyl,
- (iii) —NR9R10;
- X and Y are selected from the group consisting of
- (1) CH2, or
- (2) O,
- wherein one of X or Y is O, then the other is CH2;
- Q1, Q2, Q3 and Q4 are each selected from the group consisting of
- (1) N, or
- (2) CR3,
- provided that one of Q1, Q2, Q3 or Q4 is N and the others are each CR3;
- R3 is selected from the group consisting of
- (1) hydrogen,
- (2) halogen,
- (3) —C1-6 alkyl, or
- (4) —O—C1-6 alkyl;
- R4 is selected from the group consisting of
- (1) hydrogen,
- (2) —C1-6 alkyl,
- (3) —C3-8 cycloalkyl,
- (4) —C2-6 alkenyl,
- (5) —C0-2 alkyl-C6-10 aryl,
- (6) —C0-2 alkyl-heteroaryl group, wherein the heteroaryl is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S, wherein said alkyl, alkenyl, aryl or heteroaryl R7 group is optionally substituted with one or more
- (a) halogen,
- (b) hydroxy,
- (c) —O—C1-6 alkyl,
- (d) —C1-6 alkyl, optionally substituted with halogen;
- R5 and R6, or R7 and R8, or R9 and R10 are each independently selected from the group consisting of
- (1) hydrogen,
- (2) —C1-6 alkyl,
- (3) —C3-8 cycloalkyl, or
- (4) —C6-10 aryl,
- wherein said alkyl, cycloalkyl or aryl is optionally substituted with one or more
- (a) halogen,
- (b) —C1-6 alkyl,
- (c) —C3-8 cycloalkyl,
- (d) —O—C1-6 alkyl,
- (e) —C6-10 aryl,
- (f) heteroaryl, which is an aromatic cyclic or polycyclic cyclic, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O), SO2 or S, at least one of which is O, N, N→O, SO2 or S,
- or R5 and R6, or R7 and R8, or R9 and R10 are linked together with the nitrogen to which they are both attached to form a 4-8 membered carbocyclic ring, wherein one or two of the ring carbon atoms is replaced by a nitrogen, oxygen or sulfur, and the carbocyclic is optionally substituted with one or more
- (a) halogen,
- (b) —C1-6 alkyl,
- (c) —O—C1-6 alkyl, or
- (d) —C6-10 aryl,
- n is 0 or 1;
- or a pharmaceutically acceptable salt thereof.
67 more elements
wherein R is selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.